Summary

Esophageal Cancer Market – Scope of Report
TMR’s report on the global esophageal cancer market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2024 to 2034. The report provides revenue of the global esophageal cancer market for the period 2018–2034, considering 2024 as the base year and 2034 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global esophageal cancer market from 2024 to 2034.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the esophageal cancer market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global esophageal cancer market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global esophageal cancer market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global esophageal cancer market.

The report delves into the competitive landscape of the global esophageal cancer market. Key players operating in the global esophageal cancer market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global esophageal cancer market profiled in this report.

Key Questions Answered in Global esophageal cancer Market Report
• What is the sales/revenue generated by esophageal cancer across all regions during the forecast period?
• What are the opportunities in the global esophageal cancer market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2034?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?

Esophageal Cancer Market – Research Objectives and Research Approach
The comprehensive report on the global esophageal cancer market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global esophageal cancer market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2034 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global esophageal cancer market.

ページTOPに戻る

Table of Contents

1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Esophageal Cancer Market
4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution/Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Esophageal Cancer Market Analysis and Forecast, 2020-2034
5. Key Insights
5.1. Pipeline Analysis
5.2. Key Product /Brand Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry
6. Global Esophageal Cancer Market Analysis and Forecast, by Treatment Type
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Treatment Type, 2020-2034
6.3.1. Chemotherapy
6.3.2. Radiation Therapy
6.3.3. Targeted Therapy
6.3.4. Immunotherapy
6.3.5. Others
6.4. Market Attractiveness Analysis, by Treatment Type
7. Global Esophageal Cancer Market Analysis and Forecast, by Stage of Cancer
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Stage of Cancer, 2020-2034
7.3.1. Early-stage Esophageal Cancer
7.3.2. Advanced Esophageal Cancer
7.4. Market Attractiveness Analysis, by Stage of Cancer
8. Global Esophageal Cancer Market Analysis and Forecast, by End-user
8.1. Introduction & Definition
8.2. Key Findings/Developments
8.3. Market Value Forecast, by End-user, 2020-2034
8.3.1. Hospitals
8.3.2. Specialty Clinics
8.3.3. Cancer Treatment Centers
8.3.4. Ambulatory Surgical Centers
8.4. Market Attractiveness Analysis, by End-user
9. Global Esophageal Cancer Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region, 2020-2034
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness Analysis, by Region
10. North America Esophageal Cancer Market Analysis and Forecast
10.1. Introduction
10.2. Key Findings
10.3. Market Value Forecast, by Treatment Type, 2020-2034
10.3.1. Chemotherapy
10.3.2. Radiation Therapy
10.3.3. Targeted Therapy
10.3.4. Immunotherapy
10.3.5. Others
10.4. Market Value Forecast, by Stage of Cancer, 2020-2034
10.4.1. Early-stage Esophageal Cancer
10.4.2. Advanced Esophageal Cancer
10.5. Market Value Forecast, by End-user, 2020-2034
10.5.1. Hospitals
10.5.2. Specialty Clinics
10.5.3. Cancer Treatment Centers
10.5.4. Ambulatory Surgical Centers
10.6. Market Value Forecast, by Country, 2020-2034
10.6.1. U.S.
10.6.2. Canada
10.7. Market Attractiveness Analysis
10.7.1. By Treatment Type
10.7.2. By Stage of Cancer
10.7.3. By End-user
10.7.4. By Country
11. Europe Esophageal Cancer Market Analysis and Forecast
11.1. Introduction
11.2. Key Findings
11.3. Market Value Forecast, by Treatment Type, 2020-2034
11.3.1. Chemotherapy
11.3.2. Radiation Therapy
11.3.3. Targeted Therapy
11.3.4. Immunotherapy
11.3.5. Others
11.4. Market Value Forecast, by Stage of Cancer, 2020-2034
11.4.1. Early-stage Esophageal Cancer
11.4.2. Advanced Esophageal Cancer
11.5. Market Value Forecast, by End-user, 2020-2034
11.5.1. Hospitals
11.5.2. Specialty Clinics
11.5.3. Cancer Treatment Centers
11.5.4. Ambulatory Surgical Centers
11.6. Market Value Forecast, by Country/Sub-region, 2020-2034
11.6.1. Germany
11.6.2. U.K.
11.6.3. France
11.6.4. Italy
11.6.5. Spain
11.6.6. Rest of Europe
11.7. Market Attractiveness Analysis
11.7.1. By Treatment Type
11.7.2. By Stage of Cancer
11.7.3. By End-user
11.7.4. By Country/Sub-region
12. Asia Pacific Esophageal Cancer Market Analysis and Forecast
12.1. Introduction
12.2. Key Findings
12.3. Market Value Forecast, by Treatment Type, 2020-2034
12.3.1. Chemotherapy
12.3.2. Radiation Therapy
12.3.3. Targeted Therapy
12.3.4. Immunotherapy
12.3.5. Others
12.4. Market Value Forecast, by Stage of Cancer, 2020-2034
12.4.1. Early-stage Esophageal Cancer
12.4.2. Advanced Esophageal Cancer
12.5. Market Value Forecast, by End-user, 2020-2034
12.5.1. Hospitals
12.5.2. Specialty Clinics
12.5.3. Cancer Treatment Centers
12.5.4. Ambulatory Surgical Centers
12.6. Market Value Forecast, by Country/Sub-region, 2020-2034
12.6.1. China
12.6.2. Japan
12.6.3. India
12.6.4. Australia & New Zealand
12.6.5. Rest of Asia Pacific
12.7. Market Attractiveness Analysis
12.7.1. By Treatment Type
12.7.2. By Stage of Cancer
12.7.3. By End-user
12.7.4. By Country/Sub-region
13. Latin America Esophageal Cancer Market Analysis and Forecast
13.1. Introduction
13.2. Key Findings
13.3. Market Value Forecast, by Treatment Type, 2020-2034
13.3.1. Chemotherapy
13.3.2. Radiation Therapy
13.3.3. Targeted Therapy
13.3.4. Immunotherapy
13.3.5. Others
13.4. Market Value Forecast, by Stage of Cancer, 2020-2034
13.4.1. Early-stage Esophageal Cancer
13.4.2. Advanced Esophageal Cancer
13.5. Market Value Forecast, by End-user, 2020-2034
13.5.1. Hospitals
13.5.2. Specialty Clinics
13.5.3. Cancer Treatment Centers
13.5.4. Ambulatory Surgical Centers
13.6. Market Value Forecast, by Country/Sub-region, 2020-2034
13.6.1. Brazil
13.6.2. Mexico
13.6.3. Rest of Latin America
13.7. Market Attractiveness Analysis
13.7.1. By Treatment Type
13.7.2. By Stage of Cancer
13.7.3. By End-user
13.7.4. By Country/Sub-region
14. Middle East & Africa Esophageal Cancer Market Analysis and Forecast
14.1. Introduction
14.2. Key Findings
14.3. Market Value Forecast, by Treatment Type, 2020-2034
14.3.1. Chemotherapy
14.3.2. Radiation Therapy
14.3.3. Targeted Therapy
14.3.4. Immunotherapy
14.3.5. Others
14.4. Market Value Forecast, by Stage of Cancer, 2020-2034
14.4.1. Early-stage Esophageal Cancer
14.4.2. Advanced Esophageal Cancer
14.5. Market Value Forecast, by End-user, 2020-2034
14.5.1. Hospitals
14.5.2. Specialty Clinics
14.5.3. Cancer Treatment Centers
14.5.4. Ambulatory Surgical Centers
14.6. Market Value Forecast, by Country/Sub-region, 2020-2034
14.6.1. GCC Countries
14.6.2. South Africa
14.6.3. Rest of Middle East & Africa
14.7. Market Attractiveness Analysis
14.7.1. By Treatment Type
14.7.2. By Stage of Cancer
14.7.3. By End-user
14.7.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
15.2. Market Share Analysis, by Company (2023)
15.3. Company Profiles
15.3.1. Bristol-Myers Squibb Company
15.3.1.1. Company Overview
15.3.1.2. Product Portfolio
15.3.1.3. SWOT Analysis
15.3.1.4. Financial Overview
15.3.1.5. Strategic Overview
15.3.2. Merck & Co., Inc.
15.3.2.1. Company Overview
15.3.2.2. Product Portfolio
15.3.2.3. SWOT Analysis
15.3.2.4. Financial Overview
15.3.2.5. Strategic Overview
15.3.3. Eli Lilly and Company
15.3.3.1. Company Overview
15.3.3.2. Product Portfolio
15.3.3.3. SWOT Analysis
15.3.3.4. Financial Overview
15.3.3.5. Strategic Overview
15.3.4. AstraZeneca plc
15.3.4.1. Company Overview
15.3.4.2. Product Portfolio
15.3.4.3. SWOT Analysis
15.3.4.4. Financial Overview
15.3.4.5. Strategic Overview
15.3.5. F. Hoffmann-La Roche AG
15.3.5.1. Company Overview
15.3.5.2. Product Portfolio
15.3.5.3. SWOT Analysis
15.3.5.4. Financial Overview
15.3.5.5. Strategic Overview
15.3.6. Pfizer Inc.
15.3.6.1. Company Overview
15.3.6.2. Product Portfolio
15.3.6.3. SWOT Analysis
15.3.6.4. Financial Overview
15.3.6.5. Strategic Overview
15.3.7. Novartis AG
15.3.7.1. Company Overview
15.3.7.2. Product Portfolio
15.3.7.3. SWOT Analysis
15.3.7.4. Financial Overview
15.3.7.5. Strategic Overview
15.3.8. Sanofi S.A.
15.3.8.1. Company Overview
15.3.8.2. Product Portfolio
15.3.8.3. SWOT Analysis
15.3.8.4. Financial Overview
15.3.8.5. Strategic Overview
15.3.9. The Takeda Pharmaceutical Company Limited
15.3.9.1. Company Overview
15.3.9.2. Product Portfolio
15.3.9.3. SWOT Analysis
15.3.9.4. Financial Overview
15.3.9.5. Strategic Overview
15.3.10. Bayer AG
15.3.10.1. Company Overview
15.3.10.2. Product Portfolio
15.3.10.3. SWOT Analysis
15.3.10.4. Financial Overview
15.3.10.5. Strategic Overview